Table 3.
Growth inhibition concentration (GI50/μM) and data of N-1-naphthoyl analogs 3t and cytotoxicity (LC50/μM) 3w on various human tumor cell lines
| Panel/cell line | 3t | 3w | ||
|---|---|---|---|---|
|
| ||||
| GI50 (μM) | LC50 (μM) | GI50 (μM) | LC50 (μM) | |
| Leukemia | ||||
| CCRF-CEM | 3.35 | >100 | 3.31 | >100 |
| HL-60(TB) | 3.36 | >100 | 3.47 | >100 |
| K-562 | 3.71 | >100 | 3.52 | >100 |
| MOLT-4 | 3.49 | 79.0 | 3.95 | >100 |
| SR | 2.74 | 92.3 | 3.32 | >100 |
| Non-Small Cell Lung Cancer | ||||
| HOP-92 | 1.30 | 44.8 | 1.09 | >100 |
| Colon Cancer | ||||
| HCT-116 | 2.90 | >100 | 3.35 | >100 |
| HCT-15 | 3.60 | >100 | 3.10 | >100 |
| CNS Cancer | ||||
| SF-539 | 3.68 | 58.6 | 2.30 | >100 |
| U251 | 3.58 | 50.7 | 3.23 | >100 |
| Melanoma | ||||
| LOX IMVI | 3.59 | 55.6 | 3.80 | >100 |
| M14 | 3.22 | >100 | 1.91 | >100 |
| MDA-MB-435 | 1.91 | 9.23 | 2.01 | 12.0 |
| Ovarian Cancer | ||||
| OVCAR-3 | 2.46 | 46.2 | 2.38 | 20.9 |
| NCI/ADR-RES | 2.59 | >100 | 3.14 | >100 |
| Renal Cancer | ||||
| UO-31 | 3.93 | >100 | 3.72 | >100 |